# EDGAR Filing Document

**Accession Number:** 0001818245
**File Stem:** 0001437749-25-029807
**Filing Date:** 2025-9
**Character Count:** 7635
**Document Hash:** dc9fc81a860b09cadd211582494f9c1a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-029807.hdr.sgml**: 20250924

**ACCESSION NUMBER**: 0001437749-25-029807

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250924

**DATE AS OF CHANGE**: 20250924

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVIVA PHARMACEUTICALS HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001742927
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90624
- **FILM NUMBER:** 251338873

**BUSINESS ADDRESS:**
- **STREET 1:** 10080 N WOLFE ROAD
- **STREET 2:** SUITE SW3-200
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014
- **BUSINESS PHONE:** 4085018881

**MAIL ADDRESS:**
- **STREET 1:** 10080 N WOLFE ROAD
- **STREET 2:** SUITE SW3-200
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tenzing Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180606
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bhat Laxminarayan
- **CENTRAL INDEX KEY:** 0001818245

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 19925 STEVENS CREEK BLVD., SUITE 100
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 6)**

**REVIVA PHARMACEUTICALS HOLDINGS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**76152G100**

*(CUSIP Number)*

**Laxminarayan Bhat**<br>10080 N. Wolfe Rd., Suite SW3-200<br>Cupertino CA 95014<br>408-501-8881

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **76152G100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Bhat Laxminarayan** | Name of reporting person<br>**Bhat Laxminarayan** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**3352177.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**328697.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**3352177.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**328697.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3680874.00** | Aggregate amount beneficially owned by each reporting person<br>**3680874.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.8%** | Percent of class represented by amount in Row (11)<br>**3.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
REVIVA PHARMACEUTICALS HOLDINGS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
10080 N. WOLFE ROAD, SUITE SW3-200, CUPERTINO, CA, 95014

This Amendment No. 6 (this Amendment) amends and supplements the Schedule 13D filed on December 21, 2020, as amended and supplemented by Amendment No. 1 filed on May 5, 2023, Amendment No. 2 filed on February 16, 2024, Amendment No. 3 filed on August 23, 2024, Amendment No. 4 filed on December 20, 2024 and Amendment No. 5 filed on July 1, 2025 (the Schedule 13D), by Dr. Laxminarayan Bhat (the Reporting Person) relating to the common stock, par value $0.0001 per share (Common Stock), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the Issuer). Capitalized terms used but not defined in this Amendment have the respective meanings ascribed to such terms in the Schedule 13D. All references in the Schedule 13D and this Amendment to the Schedule 13D shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the filing date of this Amendment (the Filing Date), for purposes of Rule 13d-3 promulgated under the Act, the Reporting Person is the beneficial owner of an aggregate of 3,680,874 shares of Common Stock, which represents approximately 3.8% of the outstanding shares of Common Stock, based on 96,337,119 shares of Common Stock outstanding as of September 22, 2025, as reported directly by the Issuer to the Reporting Person.

**(b)**
Of the 3,680,874 shares of Common Stock reported as beneficially owned by the Reporting Person herein, for purposes of Rule 13d-3 under the Act, the Reporting Person: (A) has sole voting power and dispositive power with respect to an aggregate of 3,352,177 of such shares, consisting of (i) 2,478,856 shares of Common Stock held by the Reporting Person, and (ii) 873,321 shares of Common Stock issuable upon the exercise of options held by the Reporting Person that are exercisable or will be exercisable within 60 days of the Filing Date; and (B) may be deemed to share voting power and dispositive power with respect to an aggregate of 328,697 of such shares, consisting of (i) 5,388 shares of Common Stock held by the Reporting Person's spouse, and (ii) 323,309 shares of Common Stock issuable upon the exercise of options held by the Reporting Person's spouse that are exercisable or will be exercisable within 60 days of the Filing Date. The amount of shares reported as beneficially owned by the Reporting Person excludes (i) 247,130 shares of Common Stock underlying unvested options held by the Reporting Person and (ii) 86,034 shares of Common Stock underlying unvested options held by the Reporting Person's spouse, in each case that are not exercisable within 60 days of the Filing Date.

**(c)**
The Reporting Person has not effected any transactions in the Common Stock or securities convertible into, exercisable for or exchangeable for, shares of Common Stock during the period commencing 60 days prior to the Filing Date.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Bhat Laxminarayan

**Signature:** /s/ Laxminarayan Bhat

**Name/Title:** Laxminarayan Bhat

**Date:** 09/24/2025